ALOPECIA AREATA

This phase 3 trial tests whether upadacitinib (Rinvoq) can help regrow hair in people with severe alopecia areata, an autoimmune condition that causes patchy or total hair loss. About 1500 adults and teens will receive either the drug or a placebo daily for up to 160 weeks. The m…

This study tests whether transplanting healthy gut bacteria can help people with alopecia areata, an autoimmune disease that causes patchy or total hair loss. Forty adults with moderate to severe hair loss will take either antibiotic and microbiota transplant capsules or a placeb…

This study tests a new drug called LY4005130 for adults with severe alopecia areata, a condition causing significant hair loss. About 60 participants will receive either the drug or a placebo intravenously. The goal is to see if the drug can regrow hair and to check for side effe…

This phase 2 trial tests whether ruxolitinib, a drug already approved for certain blood disorders, can help regrow hair in people with APECED, a rare immune condition that often causes severe alopecia areata. About 70 participants aged 12 to 75 will take the pill twice daily for …

This study tests whether dupilumab, a drug used for allergies and eczema, can help regrow hair in people with moderate-to-severe alopecia areata who also have allergies or high IgE levels. Participants receive weekly injections of dupilumab or a placebo for 48 weeks, followed by …

This study follows 850 people with alopecia areata who are taking the approved drug ritlecitinib in real-world clinics. Researchers will measure hair regrowth using the SALT score over 24 weeks. The goal is to see how well the drug works outside of controlled trials, in everyday …

This study tests a drug called LAD603 in 136 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Participants will receive either the drug or a placebo to see if it helps regrow hair and is safe. The main goal is to measure changes in hai…

This study tests an experimental oral drug called NXC736 in 73 adults with moderate to severe alopecia areata, a condition causing patchy or total hair loss. Participants are randomly assigned to receive either NXC736 or a placebo for 12 weeks. The main goal is to see if the drug…

This study tests a new drug called BG-A3004 for the first time in humans. It aims to check the drug's safety and how the body processes it in healthy volunteers and people with immune-related skin diseases. The study is split into two parts: single dose in healthy people and mult…

This study tests if dupilumab can help children aged 6 to 17 with moderate to severe alopecia areata regrow hair. About 76 participants will receive either the drug or a placebo for 48 weeks, followed by an open-label extension. The main goal is to measure changes in scalp hair l…

This study tests a daily pill called abrocitinib for people with Down syndrome who have eczema or a type of hair loss. About 56 participants will take the drug for up to 60 weeks to see if it safely controls their skin or scalp condition. The goal is to manage symptoms, not cure …

This study tests an oral drug called deuruxolitinib in teenagers aged 12 to 17 who have lost at least half their scalp hair due to alopecia areata. The goal is to see if the drug can safely regrow hair. Participants will be randomly assigned to receive either the drug or a placeb…

This study tests whether microneedling combined with one of three substances—lactic acid, vitamin D3, or a steroid (triamcinolone acetonide)—can help regrow hair in people with patchy alopecia areata. Eighty-eight participants will receive one of the four treatments (including a …

This study tests a daily pill called upadacitinib for people with severe alopecia areata, an immune system attack on hair follicles causing at least 25% scalp hair loss. About 123 teens and adults in Japan will take either the drug or a placebo for up to 104 weeks to see if it sa…

This early-stage trial tests a drug called FB102 in 32 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Half receive the drug and half a placebo, all by IV. The main goal is to check safety, but researchers will also measure hair regro…

This program provides early access to ritlecitinib for people with severe alopecia areata who have lost at least half of their scalp hair and have not responded to or cannot tolerate standard treatments. The goal is to offer a potential treatment option before the drug is fully a…

This pilot study tests whether injecting cyclosporine directly into the scalp can safely regrow hair in people with alopecia areata, an autoimmune disease causing patchy hair loss. Twelve adults with mild to moderate hair loss will receive either cyclosporine or saline injections…

This study is testing a new laser called PALLAS to treat skin diseases like vitiligo, psoriasis, alopecia areata, and atopic dermatitis. About 50 people will receive UVB laser treatments twice a week for up to 3 months. The goal is to see if the laser improves the skin condition …

This study aims to understand how alopecia areata, vitiligo, and hidradenitis suppurativa affect the quality of life and daily functioning of teenagers and adults. Researchers will collect information from nearly 2,800 participants across multiple countries using surveys and skin…

This registry will follow 1500 adolescents aged 12-17 with severe alopecia areata, a condition causing hair loss. Researchers will collect data from routine dermatology visits to better understand the disease's natural history, how it is managed, and what treatments are used. The…

This observational study will follow about 5,000 adults with alopecia areata across North America to learn more about the condition, how it changes over time, and how it is currently treated. Researchers will collect data from doctor visits and patient surveys to better understan…